• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.26 no.2
• /
• pp.19-29
• /
• 2013

Objectives : The main purpose of this study is to investigate the efficiency of Gagamchengyoung-tang (Ji$\bar{a}$ji$\check{a}$nq$\bar{i}$ngy$\acute{i}$ng-t$\bar{a}$ng) and examine the febrile tendency in the alopecia patients Methods : Of the patients who have visited Balmers Korean Medicine clinic for alopecia from December first 2012 to December 31st 2012, we enrolled 30 patients and performed heat and cold diagnosis, examine scalp and check hair density. We administrated Gagamchengyoung-tang(Ji$\bar{a}$ji$\check{a}$nq$\bar{i}$ngy$\acute{i}$ng-t$\bar{a}$ng) and acupuncture to all patients. The effect was assessed by scalp condition and hair density Results : The scalp disorder index decreased and hair density increased in alopecia patients with febrile tendency Conclusions : All patients had febrile tendency and Gagamchengyoung-Tang(Ji$\bar{a}$ji$\check{a}$nq$\bar{i}$ngy$\acute{i}$ng-t$\bar{a}$ng) can be effective in the scalp disorder and alopecia.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.26 no.2
• /
• pp.30-44
• /
• 2013

Objectives : The purpose of this study is to report the causes and the effects of korean medicine treatment on alopecia. Methods : 1050 patients with alopecia, who had visited oriental medical clinics from July 2011 to October 2012, were analyzed by self-assessments. And 153 patients of them were treated with korean medicine treatment for 3 months. Treatment results were evaluated by patients' self-assessments and global & enlarged photographic reviews. Results : 1. The gender ratio of male to female was 2:1 and most patients belonged to the 20~30 year old group. 2. Family history of baldness in alopecia patients was a total of 57.3%, paternal 44.4% and maternal 21.2%. 3. Subjective symptoms of fever in parietal region was a total of 97.4% in alopecia patients. 4. After 1 month treatment, the fever in the parietal region was decreased by 37.3% of patients. And their subjective hair loss was also significantly decreased. 5. After 3 months of treatment, the global photographic review was improved by 56.2% of the patients and the enlarged photographic review was significantly improved by 5.2% in patients' total hair count. Conclusions : A significant number of alopecia patients were young and less relative in genetic alopecia causes was less relevant than the past. Recent causes of alopecia were more concerned with the fever in parietal region. According to that reason, cooling effect korean medicine treatment was expected to be effective for febrile alopecia, and actually had significant effects on this study. For future studies, it's long term treatment and follow up studies are needed.

• The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology
• /
• v.32 no.3
• /
• pp.164-185
• /
• 2019

Objectives : This study is carried out to analyze the use of Korean medical treatments on alopecia in Korean medicine clinical studies published in South Korea. Methods : Based on OASIS and KTKP with the keyword 'alopecia', published in 1996-2019.4.23., total 23 studies have been found and analyzed. We analyzed Korean medical treatment used in each cases, and investigated the tendency of use for each treatment. Results : 369 cases in 23 research papers were selected. Herbal medicine, acupuncture, pharmacopuncture, external medicine and other therapy were used as treatment for Alopecia. Herbal medicine with a cooling effect was mainly used. The acupoints mainly used were GV20, ST8, GB5, ST36, HT8, PC6, BL66. Pharmacopunctures used to treat alopecia were CF, HP, HH, BV, etc. The average duration of Korean medicine treatment was 144 days. After Korean medicine treatment, 292 cases presented improvement or complete recovery. Conclusions : According to the results, we were able to discover the current status of Korean medicine treatment of alopecia. Based on this result, further studies will be needed to establish the primary treatment direction of alopecia.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.19
• /
• pp.8495-8497
• /
• 2014

Purpose: To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy. Methods: This prospectively designed study focused on the safety and effectiveness of leucogen tablets 60mg three times per day for a group of cancer patients during chemotherapy for mainly lung or gastric cancers. The tablets were administered from 5 days before until the termination of chemotherapy. Neutropenia and other healthcare encounters were defined as events and occurrence was estimated for comparison. Results: We identified 39 patients receiving leucogen tablets 60mg three times per day, including 11 with gastric, 12 with lung and 16 with other sites of cancer. The mean age was 65 (29-75) years and there were 27 male and 12 female patients. The mean duration of leucogen tablets intake was 59 days. Eighteen patients were treated with taxane-based, 4 with irinotecan-based and 17 with other chemotherapy. The incidence of febrile neutropenia was 0%. Twelve patients were found severe neutropenia (grade III/IV), and the duration of severe neutropenia (grade III/IV) was 5 days. Treatment-emergent adverse events were attributable to complications of myelosuppressive chemotherapy or the primary disease (i.e., alopecia, nausea, asthenia, neutropenia, and severe hepatic renal dysfunction). No chemotherapy was delayed and no treatment related death was observed. Conclusions: This study suggested that leucogen tablets 60mg three times per day (180mg for a day) are safe and could be effective for preventing febrile neutropenia in patients with chemotherapy.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.8
• /
• pp.3419-3424
• /
• 2014

Background: Our aim was to conduct a meta-analysis to compare the efficacy and safety of pemetrexed and docetaxel for non-small cell lung cancer (NSCLC). Materials and Methods: We systematically searched the Cochrane Library, PubMed, Embase, China Biology Medicine Database for randomized controlled trials (RCTs) comparing the efficacy and toxicities of pemetrexed versus docetaxel as a treatment for advanced NSCLC. We limited the languages to English and Chinese. Two reviewers independently screened articles to identify eligible trials according to the inclusion and exclusion criteria and assessed the methodological quality of included trials, and then extracted data. The meta-analysis was performed using STATA12.0. Results: Six RCTs involving 1,414 patients were identified. We found that there was no statistically significant differences in overall response rate, survival time, progression-free survival, disease control rate, and 1-2yr survival rate (p>0.050) but it is worthy of mention that patients in the pemetrexed arms had significantly higher 3-yr survival rate (P=0.002). With regard to the grade 3 or 4 hematological toxicity, compared with docetaxel, pemetrexed led to lower rate of grade 3-4 febrile neutropenia, neutropenia, and leukocyts toxicity (p<0.001). There was no significant difference in anemia between the two arms (p=0.08). In addition, pemetrexed led to higher rate of grade 3-4 thrombocytopenia toxicity (p=0.03). As for the non-hematological toxicities, compared with docetaxel, pemetrexed group had lower rate of grade 3-4 diarrhea and alopecia. Conclusions: Pemetrexed was almost as effective as docetaxel in patients with advanced NSCLC. At the same time, pemetrexed might increase the 3-yr survival rate. As for safety, pemetrexed led to lower rate of grade 3-4 febrile neutropenia, neutropenia, leukocytes, diarrhea and alopecia toxicity. However, it was associated with a higher rate of grade 3-4 thrombocytopenia.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.9
• /
• pp.5263-5267
• /
• 2013

Background: The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer. Materials and Methods: All patients received folinic acid $400mg/m^2$ on day 1, 5-fluorouracil bolus $400mg/m^2$ on day 1, IV infusion of 5-fluorouracil $2400mg/m^2$ over 46 hours, and gemcitabine $1250mg/m^2$ on day 1. Results: A total of 29 patients with metastatic biliary tract cancer received GEMFUFOL regimen as the firstline treatment. The mean follow-up was 22.1 months (95%CI, 12.5-31.8). One patient (3.4%) achieved complete response, 5 (17.2%) had partial response, and 4 (13.8%) had stable disease. The median progression-free survival was 3.3 months (95%CI, 2.9-3.7), and the median overall survival was 8.8 months (95%CI, 3.5-14). The 1-year and 2-year survival rates were 58.6% and 30%, respectively. Grade 3 and 4 toxicity included neutropenia in 4 patients (13.7%), thrombocytopenia in 2 (6.8%), anemia2 (6.8%), and alopecia in 1 (3.4%). Two patients (6.8%) developed febrile neutropenia. A dose reduction was achieved in 8 patients (27.6%) while 5 patients had extended-interval dosage (17.2%) for toxicity. Conclusions: The GEMFUFOL chemotherapy regimen was generally efficacious and tolerable as a first-line treatment of metastatic biliary tract cancer.